GTB-5550 TriKE®
Metastatic Solid Tumors (Basket: Prostate, Ovarian, Breast, Head & Neck, NSCLC, Pancreatic, Bladder Cancers)
Phase 1 (Planned)IND Preparation - Trial initiation planned for mid-2026
Key Facts
Indication
Metastatic Solid Tumors (Basket: Prostate, Ovarian, Breast, Head & Neck, NSCLC, Pancreatic, Bladder Cancers)
Phase
Phase 1 (Planned)
Status
IND Preparation - Trial initiation planned for mid-2026
Company
About GT Biopharma
GT Biopharma is a micro-cap biotech focused on developing next-generation NK cell engagers via its proprietary TriKE® platform. The company's strategy centers on leveraging this modular technology to create potent, off-the-shelf immunotherapies that direct a patient's innate immune system against cancer. Key achievements include the ongoing Phase 1 trial for GTB-3650 in AML/MDS and the planned initiation of a Phase 1 trial for GTB-5550 in solid tumors in mid-2026. GT Biopharma's approach aims to differentiate from T-cell focused therapies by potentially offering a safer, more readily deployable treatment modality.
View full company profile